Retinal Degenerative Diseases [electronic resource] /
International Symposium on Retinal DegenerationsCorporate Author
International Symposium on Retinal Degenerations(14th :2010 :Quebec, Canada)
International Symposium on Retinal Degenerations
LaVail, Matthew M.editor.
Ash, John.editor.
Anderson, Robert E.editor.
Hollyfield, Joe G.editor.
Grimm, Christian.editor.
This book will contain the proceedings of the XIV International Symposium on Retinal Degeneration (RD2010), held July 13-17, 2010, in Mont-Tremblant, Quebec, Canada. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.
Description based upon print version of record.
Retinal Degenerative Diseases; Preface; About the Editors; Contents; Contributors; Travel Awards; Part I: AMD: Basic Mechanisms, Inflammation and Immunity; Chapter 1: A Window to Innate Neuroimmunity: Toll-Like Receptor-Mediated Cell Responses in the Retina; 1.1 Introduction; 1.2 TLRs and Neuroimmunity; 1.3 TLRs and Age-Related Macular Degeneration; 1.4 Short Interfering RNA-Based Drugs Activate TLR3 Pathways; References; Chapter 2: Autoimmune Biomarkers in Age-Related Macular Degeneration: A Possible Role Player in Disease Development and Progression; 2.1 Introduction
2.2 Evidence in Favor of a Role for Autoimmunity in AMD Pathogenesis2.3 Preliminary Results from Our Research Support the Role of Autoimmunity in AMD; 2.4 Experimental Framework and Future Directions; References; Chapter 3: Local Vs. Systemic Mononuclear Phagocytes in Age-Related Macular Degeneration and Their Regulation by CCL2-CCR2 and CX3CL1-CX3CR1 Chemokine Signalling; 3.1 Introduction; 3.2 Mononuclear Phagocytes Comprise a Heterogeneous Population of Systemic and Local Innate Immune Cells; 3.3 Activation of Mononuclear Phagocytes Is Controlled by Signals from the Microenvironment
3.4 Evidence of the Involvement of Myeloid Cells in the Pathophysiology of AMD3.5 The Identification of the Chemokine Receptor CX3CR1 as a Risk Factor for AMD; 3.6 CCR2 and CX3CR1 Signalling Contribute Differentially to the Recruitment of Monocyte Subsets to the Retina and Also Control Local Microglia Responses; 3.7 Future Directions; References; Chapter 4: Sublytic Membrane-Attack-Complex Activation and VEGF Secretion in Retinal Pigment Epithelial Cells; 4.1 Introduction; 4.2 Results; 4.3 Discussion; References; Chapter 5: Complement Activation in Retinal Degeneration; 5.1 Introduction
5.2 Methods5.3 Results; 5.4 Discussion; References; Chapter 6: Microglia in the Outer Retina and Their Relevance to Pathogenesis of Age-Related Macular Degeneration; 6.1 Introduction; 6.2 AMD Pathology in the Retinochoroidal Interface; 6.3 Microglia-RPE Interactions in the Outer Retina; 6.4 Therapeutic Perspectives; References; Chapter 7: Lutein or Zeaxanthin Supplementation Suppresses Inflammatory Responses in Retinal Pigment Epithelial Cells and Macrophages; 7.1 Introduction; 7.2 Materials and Methods; 7.2.1 Materials; 7.2.2 Experiments with Animals; 7.2.3 Cell Culture and Treatments
7.3 Results7.3.1 Supplementation with Lutein or Zeaxanthin to RPE Reduces Basal Level and LPS-Induced Secretion of IL-6 and IL-8; 7.3.2 Lutein Supplementation to Primary Macrophage Cultures Suppresses LPS-Induced Secretion of IL-6 and TNF a; 7.3.3 Macrophages Isolated from Lutein or Zeaxanthin Supplemented Mice Produce Less IL-6 and TNF a upon LPS Stimulation; 7.4 Discussion; References; Chapter 8: Exploring the Potential Role of the Oxidant-Activated Transcription Factor Aryl Hydrocarbon Receptor in the Pathogenesis of AMD; 8.1 Introduction
8.2 Oxidant Injury of RPE Cells Due to Cigarette Smoke
This book will contain the proceedings of the XIV International Symposium on Retinal Degeneration (RD2010), held July 13-17, 2010, in Mont-Tremblant, Quebec, Canada. The volume will present representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy.
Immunology.
Ophthalmology.
Geriatrics.
Gene therapy.
Immunology.
Ophthalmology.
Geriatrics/Gerontology.
Gene Therapy.

Advances in Experimental Medicine and Biology